EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013–2020

Patric Karlström, Aldina Pivodic, Ulf Dahlström, Michael Fu

Clinical Research in Cardiology · 2024

DOI: 10.1007/s00392-024-02498-z ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Research in Cardiology, 2024. Verfasst von Patric Karlström und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ryhov County Hospital, SE-551 85, Jönköping, Sweden. patric.karlstrom@rjl.se. Hauptthemen laut MEDLINE: Heart Failure, Registries, Stroke Volume, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study is aimed to compare the effectiveness of modern therapy including angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) with conventional heart failure treatment in the real world.

Background

Since ARNI and SGLT2i were introduced to treat heart failure (HF), its therapeutic regimen has modernized from previous treatment with beta-blocker (BB) and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) with mineralocorticoid receptor antagonist (MRA) as added-on in HF with reduced ejection fraction (HFrEF). However, a comparison between conventional and modern treatment strategies with drugs in combination has not been performed.

Methods

This observational study (2013–2020), using the Swedish HF Registry, involved 20,849 HF patients. Patients received either conventional (BB, ACEi/ARB, with/without MRA, n = 20,140) or modern (BB, ACEi/ARB, MRA, SGLT2i or BB, ARNI, MRA with/without SGLT2i, n = 709) treatment at the index visit. The endpoints were all-cause and cardiovascular (CV) mortality.

Results

Modern HF therapy was associated with a significant 28% reduction in all-cause mortality (adjusted HR [aHR], 0.72 (0.54–0.96); p = 0.024) and a significant 62% reduction in CV mortality (aHR, 0.38 (0.21–0.68); p = 0.0013) compared to conventional HF treatment. Similar results emerged in a sensitivity analysis using propensity score matching. The interaction analyses did not reveal any trends for EF (< 40% and ≥ 40%), sex, age (< 70 and ≥ 70 years), eGFR (< 60 and ≥ 60 ml/min/1.73 m 2 ), and etiology of HF subgroups.

Conclusion

In this nationwide study, modern HF therapy was associated with significantly reduced all-cause and CV mortality, regardless of EF, sex, age, eGFR, and etiology of HF. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureRegistriesStroke VolumeSodium-Glucose Transporter 2 InhibitorsHumansSwedenMaleFemaleAgedAngiotensin Receptor AntagonistsTreatment OutcomeVentricular Function, LeftMiddle AgedDrug Therapy, CombinationAngiotensin-Converting Enzyme InhibitorsMineralocorticoid Receptor AntagonistsAged, 80 and overNeprilysinAdrenergic beta-Antagonists

Stichwörter der Autor:innen

Angiotensin receptor-neprilysin inhibitor (ARNI)EffectivenessHeart failureReal worldSodium-glucose cotransporter 2 inhibitors (SGLT2i)

Substanzen

Sodium-Glucose Transporter 2 InhibitorsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsMineralocorticoid Receptor AntagonistsNeprilysinAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Ryhov County Hospital, SE-551 85, Jönköping, Sweden. patric.karlstrom@rjl.se.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. patric.karlstrom@rjl.se.
  • APNC Sweden, Gothenburg, Sweden.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital/Östra Hospital, University of Gothenburg, Gothenburg, Sweden.

Zitieren

APA

Karlström, P., Pivodic, A., Dahlström, U., & Fu, M. (2024). Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013–2020. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02498-z

Vancouver

Karlström P, Pivodic A, Dahlström U, Fu M. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013–2020. Clinical Research in Cardiology. 2024. doi:10.1007/s00392-024-02498-z

BibTeX
@article{Karlstrm2024,
  author = {Karlström, Patric and Pivodic, Aldina and Dahlström, Ulf and Fu, Michael},
  title = {Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013–2020},
  journal = {Clinical Research in Cardiology},
  year = {2024},
  doi = {10.1007/s00392-024-02498-z}
}
Kostenlos starten →